Deutsche Bank AG Analysts Give Thermo Fisher Scientific Inc (TMO) a $226.00 Price Target

Deutsche Bank AG set a $226.00 target price on Thermo Fisher Scientific Inc (NYSE:TMO) in a report released on Thursday, October 26th. The brokerage currently has a buy rating on the medical research company’s stock.

Several other brokerages have also recently issued reports on TMO. Leerink Swann raised their target price on Thermo Fisher Scientific from $190.00 to $207.00 and gave the stock an outperform rating in a research report on Monday, October 9th. Zacks Investment Research raised Thermo Fisher Scientific from a hold rating to a buy rating and set a $212.00 price target on the stock in a report on Thursday, September 21st. Bank of America Corporation reissued a buy rating and issued a $210.00 price target (up from $200.00) on shares of Thermo Fisher Scientific in a report on Friday, July 21st. Cowen and Company reissued an outperform rating and issued a $220.00 price target (up from $200.00) on shares of Thermo Fisher Scientific in a report on Sunday, September 10th. Finally, BidaskClub downgraded Thermo Fisher Scientific from a strong-buy rating to a buy rating in a research note on Monday, July 31st. One investment analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $205.71.

Shares of Thermo Fisher Scientific (TMO) traded down $5.71 during mid-day trading on Thursday, reaching $186.18. The company had a trading volume of 3,009,200 shares, compared to its average volume of 1,574,792. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 0.81. The stock has a market capitalization of $74,657.24, a price-to-earnings ratio of 20.46, a price-to-earnings-growth ratio of 1.71 and a beta of 1.08. Thermo Fisher Scientific has a 12 month low of $139.07 and a 12 month high of $201.20.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, beating the consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The firm had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $5.03 billion. During the same period last year, the company earned $2.03 earnings per share. The company’s revenue was up 13.9% on a year-over-year basis. research analysts predict that Thermo Fisher Scientific will post 9.36 EPS for the current year.

WARNING: This piece was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2017/11/12/thermo-fisher-scientific-inc-tmo-given-a-226-00-price-target-by-deutsche-bank-ag-analysts.html.

The business also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Investors of record on Friday, December 15th will be issued a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a yield of 0.32%. The ex-dividend date of this dividend is Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.19%.

In other Thermo Fisher Scientific news, VP Peter E. Hornstra sold 3,894 shares of the stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $185.18, for a total transaction of $721,090.92. Following the transaction, the vice president now owns 19,751 shares in the company, valued at $3,657,490.18. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jim P. Manzi sold 11,318 shares of the stock in a transaction that occurred on Friday, August 18th. The stock was sold at an average price of $172.94, for a total value of $1,957,334.92. Following the transaction, the director now owns 38,757 shares in the company, valued at approximately $6,702,635.58. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 22,738 shares of company stock worth $4,021,512. 0.49% of the stock is owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in TMO. Waldron LP lifted its position in Thermo Fisher Scientific by 48.1% during the first quarter. Waldron LP now owns 4,455 shares of the medical research company’s stock worth $661,000 after buying an additional 1,447 shares in the last quarter. Empire Life Investments Inc. increased its stake in Thermo Fisher Scientific by 132.0% during the first quarter. Empire Life Investments Inc. now owns 52,504 shares of the medical research company’s stock worth $7,861,000 after acquiring an additional 29,875 shares during the last quarter. Norinchukin Bank The increased its stake in Thermo Fisher Scientific by 5.9% during the first quarter. Norinchukin Bank The now owns 25,368 shares of the medical research company’s stock worth $3,897,000 after acquiring an additional 1,404 shares during the last quarter. Quantitative Investment Management LLC acquired a new stake in Thermo Fisher Scientific during the first quarter worth $6,512,000. Finally, Campbell & CO Investment Adviser LLC increased its stake in Thermo Fisher Scientific by 46.5% during the first quarter. Campbell & CO Investment Adviser LLC now owns 3,498 shares of the medical research company’s stock worth $537,000 after acquiring an additional 1,110 shares during the last quarter. Hedge funds and other institutional investors own 83.66% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply